John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines.Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per diluted ...
18h
BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.
BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.
Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...
Sen. Rand Paul pointed to CDC guidance on child COVID-19 vaccinations, suggesting that people are "hesitant to believe" the ...
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...
With new advancements and expansion into Rwanda, InstaDeep's journey with BioNTech begins, where will this next chapter take ...
Biontech Se Sponsored Adr ( (BNTX)) has released its Q3 earnings. Here is a breakdown of the information Biontech Se Sponsored Adr presented to its investors. BioNTech SE, a cutting-edge global ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback